Table 3

Longitudinal changes of clinical scores in three groups

AT(N)_tau	MMSE			ADAS-Cog 13			CDR-SB			FAQ
AT(N)_tau	Slope (β)	P value	FDR	Slope (β)	P value	FDR	Slope (β)	P value	FDR	Slope (β)	P value	FDR
Non-AD pathological changes vs normal biomarkers	−0.028	1.48E-04	1.48E-04	0.013	0.008	0.008	0.031	4.28.E-04	4.28E-04	0.016	0.014	0.014
AD continuum vs normal biomarkers	−0.026	1.13E-06	2.26E-06	0.018	1.97E-08	3.93E-08	0.038	1.39E-09	2.78E-09	0.034	2.27E-10	4.54E-10
Non-AD pathological changes vs AD continuum	0.003	0.809	0.809	0.004	0.617	0.617	0.006	0.629	0.659	0.018	0.134	0.134

AT(N)_NfL	MMSE			ADAS-Cog 13			CDR-SB			FAQ
AT(N)_NfL	Slope (β)	P value	FDR	Slope (β)	P value	FDR	Slope (β)	P value	FDR	Slope (β)	P value	FDR
Non-AD pathological changes vs normal biomarkers	−0.012	0.034	0.034	0.009	0.012	0.012	0.013	0.064	0.064	0.011	0.019	0.019
AD continuum vs normal biomarkers	−0.026	1.06E-05	2.11E-05	0.020	3.46E-08	6.92E-08	0.038	6.11E-08	1.22E-07	0.035	2.62E-09	5.25E-09
Non-AD pathological changes vs AD continuum	−0.013	0.120	0.120	0.009	0.078	0.078	0.025	0.015	0.023	0.024	0.005	7.50E-03

Each statistic was calculated by liner mixed model, adjusting age, sexand education years. Bold indicated that the results were statistically significant. The slopes, p values and FDR represent differences between each category.
AD, Alzheimer’s disease; ADAS-Cog 13, Alzheimer’s Disease Assessment Scale-Cognitive Subscale; CDR-SB, sum of boxes of the Clinical Dementia Rating; FAQ, Functional Assessment Questionnaire; FDR, false discovery rate; MMSE, Mini-Mental State Examination.